Edition:
India

Arrowhead Collaborator Janssen Begins Reef-1 Phase 2B Combination Study In Patients With Chronic Hepatitis B Infection


Wednesday, 28 Aug 2019 

Aug 28 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD COLLABORATOR JANSSEN BEGINS REEF-1 PHASE 2B COMBINATION STUDY IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION.ARROWHEAD PHARMACEUTICALS INC - ARROWHEAD EARNS $25 MILLION MILESTONE PAYMENT IN CONNECTION WITH TRIAL INITIATION.ARROWHEAD PHARMACEUTICALS INC - JANSSEN HAS BEGUN DOSING IN REEF-1 PHASE 2B COMBINATION STUDY IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION. 

Company Quote

35.95
-0.65 -1.78%
18 Oct 2019